Sonja Heibl

Diagnostic Performance of Initial Bone Marrow Assessment in Cytopenia: Comparison with a Genetically Informed Multidisciplinary Tumour Board Diagnosis

Bernhard Strasser, Rita Steindl, Johann Mandl, Sebastian Mustafa et autres

Background: Unexplained cytopenia represents a common diagnostic challenge in clinical haematology, reflecting either benign conditions or early manifestations of myeloid neoplasms. Methods: In this retrospective cross-sectional study, we analysed 557 patients with cytopenia who underwent initial diagnostic evaluation. The diagnostic performance of …

Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry

Simon Peter Gampenrieder, Vanessa Castagnaviz, Rupert Bartsch, Thamer Sliwa et autres

BACKGROUND: Brain metastases (BM) cause substantial morbidity and reduced survival in metastatic breast cancer (MBC). Therapeutic advances may have altered BM incidence and outcomes across subtypes. Real-world data are crucial to assess these trends and guide BM-specific clinical trials. Here, we report …

at, ch, sk (code pays fourni par la source)

AI-assisted continuous-time modelling of metastatic breast cancer reveals subtype-specific spatiotemporal organ interactions

Marc Vaisband, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Nadine Binder et autres

Abstract Metastatic breast cancer is one of the leading causes of premature mortality among women worldwide. A major barrier to optimal care is the marked heterogeneity in both the temporal dynamics of metastatic spread and the organ-specific spatial distribution of metastases. Existing …

de, sk, at (code pays fourni par la source)

AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer

Florian Huemer, Gudrun Piringer, Wolfgang Eisterer, Sonja Heibl et autres

BACKGROUND: The treatment landscape of systemic third- and later-line therapy in metastatic colorectal cancer (mCRC) continues to evolve. We, therefore, established the Austrian Group of Medical Tumor Therapy (AGMT) mCRC Registry Third-Line and Beyond to characterize clinical outcome with later-line therapies in …

at, ch, de (code pays fourni par la source)

AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer

Florian Huemer, Gudrun Piringer, Wolfgang Eisterer, Sonja Heibl et autres

The treatment landscape of systemic third- and later-line therapy in metastatic colorectal cancer (mCRC) continues to evolve. We, therefore, established the Austrian Group of Medical Tumor Therapy (AGMT) mCRC Registry Third-Line and Beyond to characterize clinical outcome with later-line therapies in routine …

AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer

Florian Huemer, Gudrun Piringer, Wolfgang Eisterer, Sonja Heibl et autres

The treatment landscape of systemic third- and later-line therapy in metastatic colorectal cancer (mCRC) continues to evolve. We, therefore, established the Austrian Group of Medical Tumor Therapy (AGMT) mCRC Registry Third-Line and Beyond to characterize clinical outcome with later-line therapies in routine …

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

Sara A. Hurvitz, Rachel M. Layman, Giuseppe Curigliano, Fabrice André et autres

PURPOSE Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway and has shown compelling activity in early clinical trials with palbociclib and fulvestrant. METHODS This phase III randomized trial (VIKTORIA-1; ClinicalTrials.gov identifier: …

us, it, fr, kr, ar, au, mx, lu, es, gb (code pays fourni par la source)

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

Michael Lauseker, Tomasz Sacha, Hana Klamova, Julia Yakoleva et autres

Currently there is no established prognostic scoring system for patients with chronic myeloid leukemia (CML) in blast phase (BP). This study aimed to identify prognostic factors of CML-BP in a large cohort of prospectively and retrospectively collected patients and to develop a …

nl, de, pl, cz, ru, gb, fr, se, it, si, at, es (code pays fourni par la source)

Abstract PS1-11-26: Esr1 mutations and use of the oral serd elacestrant in metastatic breast cancer patients in austria: results from the agmt_mbc-registry

S. P. Gampenrieder, Gabriel Rinnerthaler, A. Pichler, Walter Herz et autres

Abstract Background: Elacestrant is the first oral Selective Estrogen Receptor Degrader (SERD) to be approved in the EU as of September 2023. Since its approval, testing for mutations in the estrogen receptor 1 (ESR1) gene has become standard care for patients with …

at (code pays fourni par la source)

Abstract PS5-01-04: Clinical predictors for first-line treatment duration in HER2-positive metastatic breast cancer Results from the AGMT_MBC-Registry

Gabriel Rinnerthaler, S. P. Gampenrieder, A. Pichler, Walter Herz et autres

Abstract Background: Based upon the CLEOPATRA trial, a combination of docetaxel plus trastuzumab and pertuzumab (THP) has been the standard treatment for patients with metastatic HER2-positive breast cancer. However, this standard has recently been challenged by the results of the DESTINY-Breast09 study, …

at (code pays fourni par la source)

Abstract PS2-04-08: Incidence of second primary tumors and second primary breast cancers events in patients with metastatic breast cancer: results from the Austrian AGMT_MBC-Registry

Vanessa Castagnaviz, S. P. Gampenrieder, A. Pichler, Walter Herz et autres

Abstract Background: Second primary tumors (SPTs) occur in approximately 10% of patients following an initial cancer diagnosis and are associated with increased cancer-related mortality. Ongoing advancements in systemic therapies have led to a growing population of both breast cancer (BC) survivors and …

at (code pays fourni par la source)

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Lisa Pleyer, Xu Zhang, Manuel Drost, Hubert Angermann et autres

Abstract Introduction Morphologic complete remission (CR) or composite CR (cCR) requiring bone marrow evaluations (BMEs) remain the gold standard for response assessment in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelodysplastic neoplasms (MDS). Response criteria still vary by disease subgroup, …

at, se, us (code pays fourni par la source)